Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Johnson & Johnson's Tecvayli (teclistamab) wins EU label expansion for relapsed or refractory multiple myeloma in second-line Ph3
Antibody, cancer, bispecific T-cell engager, multiple myeloma, BCMA target, combination therapy - Read more

Genmab's (rinatabart sesutecan) beats survival endpoints in Ph3 folate receptor alpha-targeting trial for platinum-resistant ovarian cancer
Antibody-drug conjugate, cancer, ovarian cancer, FRα target, platinum-resistant ovarian cancer - Read more

Amgen's Imdelltra (tarlatamab) cuts death risk 58% in extensive-stage small cell lung cancer Ph3 trial
Antibody, cancer, bispecific T cell engager, small cell lung cancer, DLL3 target, combination therapy - Read more

Johnson & Johnson's JNJ-6143 (JNJ-6143) shows 75% overall response rate in Ph1 metastatic castration-resistant prostate cancer trial
Small molecule, cancer, prostate cancer, RIPTAC, induced proximity, androgen receptor - Read more

Merck & Co., Kelun-Biotech's (sacituzumab tirumotecan) cuts death risk 32% in advanced endometrial cancer in Ph3
Antibody-drug conjugate, cancer, endometrial cancer, TROP2, topoisomerase I inhibitor, non-small cell lung cancer - Read more

AstraZeneca's Tagrisso (osimertinib)-Orpathys (savolitinib) combo shows Ph3 PFS, OS gains in EGFR-mutated, MET-overexpressed non-small-cell lung cancer
Small molecule, cancer, non-small cell lung cancer, EGFR mutation, MET amplification, combination therapy - Read more

Roche's (sefaxersen) hits Ph3 primary endpoint, reducing proteinuria by 43.1% in immunoglobulin A nephropathy
Antisense oligonucleotide, kidney disease, IgA nephropathy, complement factor B, proteinuria - Read more

Merck & Co., Kelun-Biotech's (sacituzumab tirumotecan) cuts progression risk 51% in PD-L1-negative non-small cell lung cancer Ph3
Antibody-drug conjugate, cancer, non-small cell lung cancer, TROP2, PD-L1, combination therapy - Read more

Bayer's Nubeqa (darolutamide) shows Ph3 metastasis-free survival benefit in very high-risk localized prostate cancer
Small molecule, cancer, androgen receptor inhibitor, prostate cancer, metastasis-free survival, combination therapy - Read more

Bristol Myers Squibb's (izalontamab brengitecan) achieves '5 out of 5' Ph3 wins across non-small cell lung cancer and breast cancer
Antibody-drug conjugate, cancer, bispecific ADC, non-small cell lung cancer, breast cancer, EGFR/HER3 target - Read more

Akeso, Summit Therapeutics' (ivonescimab) beats AstraZeneca's Imfinzi in Ph3 biliary tract cancer trial with 25% lower death risk
Antibody, cancer, bispecific antibody, biliary tract cancer, PD-1/VEGF, combination therapy - Read more

AstraZeneca's sonesitatug vedotin (Sone-Ve) doubles overall survival in advanced gastric cancer in Ph3 trial
Antibody-drug conjugate, cancer, gastric cancer, CLDN18.2, ADC - Read more

Roche's divarasib cuts death risk 44% vs. first-generation agents in Ph3 non–small-cell lung cancer trial
Small molecule, cancer, KRAS G12C inhibitor, non-small cell lung cancer, KRAS mutation, combination therapy - Read more

Incyte reports Ph1 data for (INCB161734) targeting KRAS G12D in pancreatic ductal adenocarcinoma, advancing to Ph3
Small molecule, cancer, KRAS G12D inhibitor, pancreatic cancer, combination therapy - Read more

Bristol Myers Squibb, BioNTech's pumitamig (PD-L1xVEGF-A) shows 36.7% response rate in Ph2 metastatic non-small cell lung cancer trial
Bispecific antibody, cancer, non-small cell lung cancer, PD-L1, VEGF-A, combination therapy - Read more

AstraZeneca's Imfinzi (durvalumab) plus Pfizer and Astellas' Padcev (enfortumab vedotin) cuts death risk 42% in muscle-invasive bladder cancer Ph3
Antibody, cancer, antibody-drug conjugate, bladder cancer, PD-L1 inhibitor, combination therapy - Read more

Novartis' (remibrutinib) meets Ph3 primary endpoints but shows modest relapse reductions in relapsing multiple sclerosis
Small molecule, neurological, BTK inhibitor, multiple sclerosis, relapsing multiple sclerosis - Read more

Johnson & Johnson's Rybrevant (amivantamab) achieves 77% overall response rate in Ph1b/2 first-line head and neck squamous cell carcinoma
Antibody, cancer, bispecific antibody, head and neck squamous cell carcinoma, EGFR target, combination therapy - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Pathos AI raises $237M Series E, led by Bristol Myers Squibb, scaling AI-driven drug development platform
AI/ML platform, oncology, neurological, antibody-drug conjugate, clinical-stage, platform-enabled - Read more

EQT acquires Qiagen for €10.8B ($12.1B), taking molecular diagnostics specialist private
Molecular diagnostics, life sciences, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Bristol Myers Squibb's (zolacabtagene autoleucel) linked to patient death from septic pneumonia in Ph1 multiple sclerosis trial
Cell therapy, autoimmune, CAR-T, multiple sclerosis, cytokine release syndrome, ICANS - Read more

BioNTech's (trastuzumab pamirtecan) Ph3 shows modest efficacy, higher interstitial lung disease rates in HER2-low metastatic breast cancer
Antibody-drug conjugate, cancer, breast cancer, HER2, trastuzumab pamirtecan, ILD toxicity - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here